Trastuzumab is a monoclonal antibody used primarily in the treatment of HER2-positive breast cancer. It targets the HER2 protein, which is overexpressed in certain types of breast cancer, leading to the inhibition of cancer cell growth. Trastuzumab has significantly improved outcomes for patients with HER2-positive malignancies.